A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer

医学 前列腺切除术 前列腺癌 临床终点 泌尿科 泌尿生殖系统 放射治疗 不利影响 人口 放射外科 外科 癌症 内科学 随机对照试验 环境卫生
作者
Liat Hammer,Ralph Jiang,Jason W.D. Hearn,Jack Lashbrook,Amyre L. Mitchell,Stephanie Daignault‐Newton,Robert T. Dess,Will Jackson,Zachery R. Reichert,Joshi J. Alumkal,Samuel D. Kaffenberger,Arvin K. George,Jeffrey S. Montgomery,Simpa S. Salami,Todd M. Morgan,David S. Miller,Daniela Wittman,Brent K. Hollenbeck,Rohit Mehra,Matthew S. Davenport
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:115 (1): 132-141 被引量:5
标识
DOI:10.1016/j.ijrobp.2022.07.016
摘要

Purpose Men with locally advanced prostate cancer who undergo radical prostatectomy (RP) often develop recurrence and require postoperative radiotherapy. We aimed to determine the safety of neoadjuvant stereotactic body radiotherapy (SBRT) before RP in this population. Methods and Patients A single-institution phase 1 trial (NCT02946008) of men with high-risk or node-positive prostate cancer were enrolled between March and October 2017. The primary endpoint was to determine the maximum tolerated dose of SBRT based on a composite 30-day post-RP toxicity goal of ≤28% of patients experiencing a dose-limiting toxicity (DLT). Secondary outcomes included toxicity, efficacy, and multiple quality of life (QoL) inventories. SBRT (30-35 Gy/5 fractions) was delivered to the prostate and seminal vesicles, and 25 Gy/5 fractions to the pelvic lymph nodes. RP was performed for a median of 6 weeks post-SBRT. Hormone therapy was not allowed. Results Median follow-up was 40 months (range, 33-44). Twenty-five percent of the patients (n = 4) experienced a DLT within 30 days post-RP; however, the trial was stopped early (n = 16 of planned 38 patients) owing to the proportion and severity of the late adverse events. Post-RP grade 3 genitourinary and gastrointestinal toxicities occurred in 75% (n = 12) and 25% (n = 4) of patients, respectively. Two patients required cystectomy and urinary diversion ≥2 years post-RP. At 24 months post-RP, 75% (n = 12) of men used ≥1 pad/d and 0% had erections suitable for intercourse. Surgical margins were negative in all patients and 31% (n = 5) had complete or partial (pre-RP) MRI-response to SBRT. Three-year biochemical recurrence and distant metastasis were 45% (95% CI, 5%-68%) and 28% (95% CI, 0%-49%), respectively. Conclusions Neoadjuvant SBRT followed by RP resulted in unacceptably high toxicity and severe QoL declines. Men with locally advanced prostate cancer who undergo radical prostatectomy (RP) often develop recurrence and require postoperative radiotherapy. We aimed to determine the safety of neoadjuvant stereotactic body radiotherapy (SBRT) before RP in this population. A single-institution phase 1 trial (NCT02946008) of men with high-risk or node-positive prostate cancer were enrolled between March and October 2017. The primary endpoint was to determine the maximum tolerated dose of SBRT based on a composite 30-day post-RP toxicity goal of ≤28% of patients experiencing a dose-limiting toxicity (DLT). Secondary outcomes included toxicity, efficacy, and multiple quality of life (QoL) inventories. SBRT (30-35 Gy/5 fractions) was delivered to the prostate and seminal vesicles, and 25 Gy/5 fractions to the pelvic lymph nodes. RP was performed for a median of 6 weeks post-SBRT. Hormone therapy was not allowed. Median follow-up was 40 months (range, 33-44). Twenty-five percent of the patients (n = 4) experienced a DLT within 30 days post-RP; however, the trial was stopped early (n = 16 of planned 38 patients) owing to the proportion and severity of the late adverse events. Post-RP grade 3 genitourinary and gastrointestinal toxicities occurred in 75% (n = 12) and 25% (n = 4) of patients, respectively. Two patients required cystectomy and urinary diversion ≥2 years post-RP. At 24 months post-RP, 75% (n = 12) of men used ≥1 pad/d and 0% had erections suitable for intercourse. Surgical margins were negative in all patients and 31% (n = 5) had complete or partial (pre-RP) MRI-response to SBRT. Three-year biochemical recurrence and distant metastasis were 45% (95% CI, 5%-68%) and 28% (95% CI, 0%-49%), respectively. Neoadjuvant SBRT followed by RP resulted in unacceptably high toxicity and severe QoL declines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
可爱的函函的应助被haoren采纳,获得10
1秒前
万能图书馆的应助被葱诚采纳,获得10
2秒前
史育川完成签到 ,获得积分10
2秒前
明亮的新筠的应助被清泠采纳,获得10
3秒前
归去来完成签到,获得积分10
3秒前
Clark完成签到,获得积分0
3秒前
yanxiaoling完成签到,获得积分20
4秒前
4秒前
4秒前
6秒前
6秒前
怡然剑成完成签到 ,获得积分0
8秒前
8秒前
老韩发布了新的文献求助20
8秒前
Akim的应助被王光宇采纳,获得10
10秒前
hujuan发布了新的文献求助10
10秒前
从容冷安完成签到 ,获得积分10
10秒前
星星发布了新的文献求助10
11秒前
12秒前
印度free饼完成签到,获得积分10
12秒前
蓝天下载发布了新的文献求助10
13秒前
14秒前
李爽完成签到,获得积分20
14秒前
phhhhh发布了新的文献求助10
14秒前
14秒前
LUO发布了新的文献求助10
15秒前
JamesPei的应助被董欣雨采纳,获得10
15秒前
华仔的应助被轻松峻熙采纳,获得10
17秒前
枫楠完成签到,获得积分10
18秒前
田様的应助被星星采纳,获得10
18秒前
Nole的应助被庾傀斗采纳,获得10
20秒前
风趣忻完成签到,获得积分20
20秒前
20秒前
科研通AI6.3的应助被归去来采纳,获得10
21秒前
22秒前
23秒前
小二郎的应助被wangjie77采纳,获得100
23秒前
爆米花的应助被谋勇兼备采纳,获得30
24秒前
赘婿的应助被TEDDY采纳,获得10
24秒前
Akim的应助被兮云采纳,获得10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188394
求助须知:如何正确求助?哪些是违规求助? 9576268
关于积分的说明 21846207
捐赠科研通 7786486
什么是DOI,文献DOI怎么找? 3435317
关于科研通互助平台的介绍 2559618
邀请新用户注册赠送积分活动 2482322